Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

VJVirtual | Enasidenib for IDH2-mutated MDS

Valeria Santini • 17 Mar 2020
Myelodysplastic Syndromes Enasidenib

Valeria Santini, MD, University of Florence, Florence, Italy, gives us a round-up of some of the exciting trials currently taking place in the myelodysplastic syndromes (MDS) space. Specifically, Dr Santini outlined the use of enasidenib for IDH2-mutated MDS. This interview was filmed via an online conference call with VJHemOnc.

More from Valeria Santini

Key debates in MDS at ASH 2025: diagnosis, pre-disease therapy, & more 2:53
Key debates in MDS at ASH 2025: diagnosis, pre-disease therapy, & more
Valeria Santini • 5 Dec 2025
Long-term survival results from COMMANDS: luspatercept versus EPO in LR-MDS 2:30
Long-term survival results from COMMANDS: luspatercept versus EPO in LR-MDS
Valeria Santini • 5 Dec 2025
Long-term outcomes from the Phase III IMerge trial of imetelstat in LR-MDS 2:26
Long-term outcomes from the Phase III IMerge trial of imetelstat in LR-MDS
Valeria Santini • 5 Dec 2025
Lower-risk MDS: improving outcomes with luspatercept, imetelstat & new agents 7:55
Lower-risk MDS: improving outcomes with luspatercept, imetelstat & new agents
Valeria Santini • 5 Sep 2025

Related Videos

Correlation between treatment-emergent cytopenias and clinical response with imetelstat in LR-MDS 1:10
Correlation between treatment-emergent cytopenias and clinical response with imetelstat in LR-MDS
Amer Zeidan • 5 Dec 2025
Luspatercept initiated at the maximum-approved dose in transfusion-dependent LR-MDS: MAXILUS trial 1:11
Luspatercept initiated at the maximum-approved dose in transfusion-dependent LR-MDS: MAXILUS trial
Amer Zeidan • 5 Dec 2025
A Phase II decentralized clinical trial of ivosidenib in IDH1-mutated CCUS 3:19
A Phase II decentralized clinical trial of ivosidenib in IDH1-mutated CCUS
Abhay Singh • 6 Dec 2025
An upcoming Phase II trial of eltrombopag in low-risk MDS and CMML harboring TET2 mutations 1:54
An upcoming Phase II trial of eltrombopag in low-risk MDS and CMML harboring TET2 mutations
Abhay Singh • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals